Prognostic, predictive, and surrogate factors for individualizing treatment for men with castration-resistant prostate cancer.
With the surge in therapeutic options for castration-resistant prostate cancer (CRPC) comes increasingly complicated treatment decision making, highlighting the need for biomarkers that can identify appropriate patients for specific treatments and accurately assess disease response. Here we discuss existing and potential prognostic, predictive, and surrogate biomarkers in CRPC.
From the Duke Cancer Institute and the Duke Prostate Center, Durham, NC.
Rhonda L
RL
Bitting
From the Duke Cancer Institute and the Duke Prostate Center, Durham, NC.
Andrew J
AJ
Armstrong